BioSpace News Archive

Scilex Holding Company, a nearly 100% majority-owned subsidiary of Sorrento Therapeutics, Inc., announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective May 18, 2022.

XBiotech announced that the French National Agency for the Safety of Medicines and Health Products [L’Agence nationale de sécurité du médicament et des produits de santé ] approved the launch of a multicenter randomized clinical study for XBiotech’s candidate cancer treatment Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer.

CardieX Limited, a global health technology company focused on cardiovascular disease and vascular health disorders, is pleased to announce the appointment of Lesa Musatto to its Board of Directors as a US-based Non-executive Director, effective immediately.

Abbott (NYSE: ABT) today announced U.S. availability of its Amplatzer™ Steerable Delivery Sheath, which is used with the company’s Amplatzer Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at risk of ischemic stroke.

Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update.

Relmada Therapeutics, Inc. today announced that it will report its financial results for the first quarter ended March 31, 2022 after the market close on Thursday, May 5, 2022.

THINK Surgical, Inc., a leading innovator in the field of robotic surgery, is pleased to announce a collaborative project between Concordia University and THINK Surgical funded by the Natural Sciences and Engineering Research Council of Canada and MEDTEQ+.

Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, announced the 2022 class of Harrington Scholar-Innovators.

Harvard University spinout advances a unique complementary metal-oxide-semiconductor -powered drug discovery platform that opens a new dimension in cell-based screening

Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies to develop once-yearly therapeutics for chronic conditions, today announced that it has initiated and dosed the first subjects in a phase 1 clinical trial of DLP-160, a 6-12-month formulation of naltrexone for the treatment of opioid use disorder (OUD).